Donovan Joanne M.
Known title: CMOCIK: 0001644087
Associated companies
Transaction History
| EWTX | ▼ Sell | Open Market | 2,919 | $127K | 8/13/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,781 | $0 | 8/12/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 7,031 | $0 | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,839 | $124K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,779 | $121K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 104 | $5K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 800 | $36K | 8/12/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 50,000 | $354K | 5/5/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 50,000 | $1.9M | 5/5/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 5,230 | $164K | 5/4/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 28,662 | $203K | 4/1/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 28,662 | $926K | 4/1/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 21,338 | $151K | 3/31/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 21,338 | $685K | 3/31/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 9,623 | $298K | 3/27/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 6,735 | $209K | 3/27/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,781 | $0 | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,862 | $38K | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 5,187 | $85K | 5/2/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 10,417 | $0 | 5/1/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 25,000 | $177K | 1/28/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 25,000 | $691K | 1/28/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 7,162 | $203K | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 3,682 | $70K | 5/2/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 10,417 | $0 | 5/1/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 3,254 | $29K | 5/2/2023 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 10,416 | $0 | 5/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial
Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.